Search for:

Webmail
UCD Access
Canvas
Quick Links

Innovations

Disclose an Invention

Learn About Us

Team

News & Events

Data & Metrics

Careers

Contact

FAQ
I'm a Campus Innovator

Healthcare Innovation & Entrepreneurship Initiative

Faculty Resources

Funding Resources
I'm an Industry Partner

I'm With a Company

I'm an Entrepreneur or Investor
I'm a Student

Student IP Policy

Fellowships

OncoVerity Secures Extended Series A to Advance cusatuzumab in Newly Diagnosed AML

New hope for those with limited treatment options

by Business Wire | November 21, 2024

First patients dosed in OV-AML-1231, a Phase 2 randomized controlled trial of cusatuzumab in newly diagnosed AML

Topics: Press Coverage

Spread the word:

Related Articles

Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Aurora, CO 80045

303-724-3720

Twitter YouTube LinkedIn Vimeo

Partners

Children's Hospital of Colorado Center for Innovation

Colorado Clinical and Translational Sciences Institute

Fitzsimons Innovation Community

UCHealth Innovation Center

Contact Us
Website Feedback
CU System
Privacy Policy
Terms of Use
Accessibility
Accreditation
Employment
Give Now

© 2025 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.